enGene Therapeutics Statistics
NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.74-0.02 (-1.14%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
enGene Therapeutics by the numbers
enGene Therapeutics has a market capitalization of $116.6 million based on 67.02M shares outstanding. With trailing EPS of $-2.07, enGene Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 2.6% below its 50-day average and 53.6% below its 200-day average.
Average daily trading volume is 1.12M shares, or about $1.9 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
ENGN valuation vs. peer median
| Metric | ENGN | Peer median | Difference |
|---|---|---|---|
| Market cap | $116.61M | $112.26M | +4% |
| Avg. volume | 1.12M | 1.37M | -18% |
Peer median across 8 companies: IVVD, ARMP, HUMA, CMPX, FATE, CRDL, MOLN, IPHA.
Valuation
- Market cap
- $116.61M
- EPS (TTM)
- $-2.07
- Shares outstanding
- 67.02M
Price and trading
- Previous close
- 1.76
- Open
- 1.75
- Day range
- 1.69 – 1.80
- 52-week range
- 1.40 – 12.25
- 52-week change
- -75.00%
- Beta
- —
- Volume
- 556.72K
- Average volume
- 1.12M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Sep 8, 2026
Additional statistics
- Market Cap
- 116.61M
- Forward Pe
- -1.09
- Eps
- -2.07
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 12.25
- Week52 Low
- 1.40
- Avg Volume
- 1.12M
- Shares Outstanding
- 67.02M
- Ma50
- 1.79
- Ma200
- 3.75
- Earnings Date
- Sep 8, 2026
- Pct From52w High
- -85.80%
- Pct From52w Low
- 24.29%